New Jersey, USA-based Merck & Co has been granted a Priority Review from the US regulator for its pulmonary arterial hypertension (PAH) candidate sotatercept. 29 September 2023
Shares in New York-based stem cell specialist BrainStorm Cell Therapeutics have fallen around half ahead of the opening bell, after the firm provided a negative 28 September 2023
Ophthalmic company Ocuphire Pharma (Nasdaq: OCUP), a specialist in retinal and refractive eye disorders, together with partner Viatris (Nasdaq: VTRS), have secu 27 September 2023
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Coherus BioSciences’ application for Udenyca Onbody, the company's on-b 26 September 2023
Ahead of a panel meeting of the US Food and Drug Administration’s scientists, the agency’s briefing notes paint a pessimistic picture for the amyotrophic latera 26 September 2023
French pharma major Sanofi and US biotech Regeneron’s blockbuster monoclonal antibody Dupixent (dupilumab) is nearing another indication in the USA. 26 September 2023
It may feel like groundhog day for the beleaguered backers of a novel drug-device product developed by biotech unicorn Intarcia Therapeutics. 22 September 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.